Prime Medicine, Inc. (PRME)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Collaboration revenue | 1,115 | 1,454 | 209 | - |
| Research and development | 41,375 | 40,562 | 40,340 | 43,071 |
| General and administrative | 13,117 | 13,284 | 14,101 | 12,601 |
| Total operating expenses | 54,492 | 53,846 | 54,441 | 55,672 |
| Loss from operations | -53,377 | -52,392 | -54,232 | -55,672 |
| Other income, net | 18 | 37 | -83 | 39 |
| Interest income | 743 | 1,182 | 697 | 611 |
| Amortization of premiums and discount on short-term investments | 530 | 339 | 885 | 1,486 |
| Change in fair value of short-term investment related party | -505 | -1,056 | 215 | -1,925 |
| Total other income, net | 786 | 502 | 1,714 | 211 |
| Net loss before income taxes | -52,591 | -51,890 | -52,518 | -55,461 |
| Provision for income taxes | - | - | - | -134 |
| Net loss attributable to common stockholders, basic | -52,591 | -51,890 | -52,518 | -55,327 |
| Net loss attributable to common stockholders, diluted | -52,591 | -51,890 | -52,518 | -55,327 |
| Net loss per share attributable to common stockholders, basic (in dollars per share) | -0.41 | -0.4 | -0.44 | -0.46 |
| Net loss per share attributable to common stockholders, diluted (in dollars per share) | -0.41 | -0.4 | -0.44 | -0.46 |
| Weighted-average common shares outstanding, basic (in shares) | 129,185,918 | 130,884,490 | 119,764,270 | 119,188,866 |
| Weighted-average common shares outstanding, diluted (in shares) | 129,185,918 | 130,884,490 | 119,764,270 | 119,188,866 |